Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Goldstein, 2014, Multicenter retrospective analysis of metastatic CRC with high-level microsatellite instability (MSI-H), Ann Oncol, 25, 1032, 10.1093/annonc/mdu100

Koopman, 2009, Deficient mismatch repair system in patients with sporadic advanced colorectal cancer, Br J Cancer, 100, 266, 10.1038/sj.bjc.6604867

Venderbosch, 2014, Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies, Clin Cancer Res, 20, 5322, 10.1158/1078-0432.CCR-14-0332

Tran, 2011, Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer, Cancer, 117, 4623, 10.1002/cncr.26086

Giannakis, 2016, Genomic correlates of immune-cell infiltrates in colorectal carcinoma, Cell Rep, 15, 857, 10.1016/j.celrep.2016.03.075

Llosa, 2015, The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints, Cancer Discov, 5, 43, 10.1158/2159-8290.CD-14-0863

Saeterdal, 2001, Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer, Proc Natl Acad Sci USA, 98, 13255, 10.1073/pnas.231326898

Schwitalle, 2008, Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers, Gastroenterology, 134, 988, 10.1053/j.gastro.2008.01.015

Le, 2016, Programmed death-1 blockade in mismatch repair deficient colorectal cancer, J Clin Oncol, 34, 103, 10.1200/JCO.2016.34.15_suppl.103

Brahmer, 2010, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates, J Clin Oncol, 28, 3167, 10.1200/JCO.2009.26.7609

Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596

Eisenhauer, 2009, New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Aaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093/jnci/85.5.365

1990, EuroQol—a new facility for the measurement of health-related quality of life, Health Policy, 16, 199, 10.1016/0168-8510(90)90421-9

Osoba, 1998, Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol, 16, 139, 10.1200/JCO.1998.16.1.139

Domingo, 2005, BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes, Oncogene, 24, 3995, 10.1038/sj.onc.1208569

Yaeger, 2012, BRAF mutations in colorectal cancer: clinical relevance and role in targeted therapy, J Natl Compr Canc Netw, 10, 1456, 10.6004/jnccn.2012.0148

Di Nicolantonio, 2008, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer, J Clin Oncol, 26, 5705, 10.1200/JCO.2008.18.0786

De Roock, 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, Lancet Oncol, 11, 753, 10.1016/S1470-2045(10)70130-3

Kopetz, 2017, Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406), J Clin Oncol, 35, 520, 10.1200/JCO.2017.35.4_suppl.520

Corcoran, 2016, Ann Oncol, 27, 149, 10.1093/annonc/mdw370.04

Janssen, 2014, Population norms for the EQ-5D, 19

Antonia, 2016, Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial, Lancet Oncol, 17, 883, 10.1016/S1470-2045(16)30098-5

Ferris, 2016, Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N Engl J Med, 375, 1856, 10.1056/NEJMoa1602252

2016

Andre, 2017, Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study, Proc Am Soc Clin Oncol, 35, 3531, 10.1200/JCO.2017.35.15_suppl.3531

Sueda, 2016, Efficacy and safety of regorafenib or TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies, Anticancer Res, 36, 4299

Grothey, 2013, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet, 381, 303, 10.1016/S0140-6736(12)61900-X

Mayer, 2015, Randomized trial of TAS-102 for refractory metastatic colorectal cancer, N Engl J Med, 372, 1909, 10.1056/NEJMoa1414325